|
Gene: C16orf62 |
Gene summary for C16ORF62 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C16orf62 | Gene ID | 57020 |
Gene name | VPS35 endosomal protein sorting factor like | |
Gene Alias | C16orf62 | |
Cytomap | 16p12.3 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KT69 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57020 | C16orf62 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.45e-30 | 5.14e-01 | 0.294 |
57020 | C16orf62 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 7.89e-03 | 4.33e-01 | 0.3487 |
57020 | C16orf62 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.54e-35 | 9.08e-01 | 0.281 |
57020 | C16orf62 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.40e-09 | 2.12e-01 | 0.3859 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C16orf62 | SNV | Missense_Mutation | rs750664367 | c.742N>T | p.Arg248Trp | p.R248W | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-55-8508-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
C16orf62 | SNV | Missense_Mutation | c.778N>T | p.Gly260Cys | p.G260C | protein_coding | deleterious(0.03) | probably_damaging(0.955) | TCGA-86-8585-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
C16orf62 | SNV | Missense_Mutation | rs534959158 | c.572G>A | p.Arg191His | p.R191H | protein_coding | deleterious(0.03) | benign(0.026) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
C16orf62 | SNV | Missense_Mutation | c.973G>T | p.Asp325Tyr | p.D325Y | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-97-A4M0-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
C16orf62 | SNV | Missense_Mutation | c.2666A>C | p.Glu889Ala | p.E889A | protein_coding | tolerated(0.47) | benign(0.05) | TCGA-L9-A8F4-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
C16orf62 | SNV | Missense_Mutation | c.399N>C | p.Lys133Asn | p.K133N | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-18-3417-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | SD | ||
C16orf62 | SNV | Missense_Mutation | novel | c.604N>T | p.Asp202Tyr | p.D202Y | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-43-8118-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
C16orf62 | SNV | Missense_Mutation | c.268N>G | p.Met90Val | p.M90V | protein_coding | deleterious(0.01) | benign(0.011) | TCGA-60-2695-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
C16orf62 | SNV | Missense_Mutation | novel | c.526N>T | p.Asp176Tyr | p.D176Y | protein_coding | deleterious(0) | possibly_damaging(0.656) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
C16orf62 | SNV | Missense_Mutation | c.268N>G | p.Met90Val | p.M90V | protein_coding | deleterious(0.01) | benign(0.011) | TCGA-66-2758-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |